| Year |
Citation |
Score |
| 2023 |
Haque R, Chen LH, Oestreicher N, Lalla D, Chlebowski RT. Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan. Breast Cancer (Dove Medical Press). 15: 637-645. PMID 37605715 DOI: 10.2147/BCTT.S420061 |
0.325 |
|
| 2022 |
Hendrix N, Oestreicher N, Lalla D, Dolan CM, Fisher KA, Veenstra DL, Moy B. Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clinical Breast Cancer. PMID 36220724 DOI: 10.1016/j.clbc.2022.08.012 |
0.504 |
|
| 2021 |
Mahtani R, Oestreicher N, Lalla D, Ogbonnaya A, Saundankar V, Willey J, Coutinho AD, McCann K. Health Care Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents. Clinical Breast Cancer. PMID 35067467 DOI: 10.1016/j.clbc.2021.11.013 |
0.351 |
|
| 2019 |
Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 31089966 DOI: 10.1007/S40273-019-00809-1 |
0.435 |
|
| 2018 |
Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 30194623 DOI: 10.1007/S40273-018-0709-3 |
0.446 |
|
| 2010 |
Conroy SM, Butler LM, Harvey D, Gold EB, Sternfeld B, Oestreicher N, Greendale GA, Habel LA. Physical activity and change in mammographic density: the Study of Women's Health Across the Nation. American Journal of Epidemiology. 171: 960-8. PMID 20354074 DOI: 10.1093/Aje/Kwq025 |
0.389 |
|
| 2010 |
Butler LM, Gold EB, Conroy SM, Crandall CJ, Greendale GA, Oestreicher N, Quesenberry CP, Habel LA. Active, but not passive cigarette smoking was inversely associated with mammographic density. Cancer Causes & Control : Ccc. 21: 301-11. PMID 19915951 DOI: 10.1007/S10552-009-9462-4 |
0.316 |
|
| 2009 |
Oestreicher N. Costs of adjuvant breast cancer treatments. Cancer Treatment and Research. 151: 421-40. PMID 19593526 DOI: 10.1007/978-0-387-75115-3_25 |
0.365 |
|
| 2008 |
Oestreicher N, Capra A, Bromberger J, Butler LM, Crandall CJ, Gold EB, Greendale GA, Modugno F, Sternfeld B, Habel LA. Physical activity and mammographic density in a cohort of midlife women. Medicine and Science in Sports and Exercise. 40: 451-6. PMID 18379206 DOI: 10.1249/Mss.0B013E31815F5B47 |
0.355 |
|
| 2008 |
Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) Lung Cancer. 61: 405-415. PMID 18295368 DOI: 10.1016/J.Lungcan.2007.12.023 |
0.526 |
|
| 2008 |
Butler LM, Gold EB, Greendale GA, Crandall CJ, Modugno F, Oestreicher N, Quesenberry CP, Habel LA. Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN). Breast Cancer Research and Treatment. 112: 165-74. PMID 18066689 DOI: 10.1007/S10549-007-9840-0 |
0.397 |
|
| 2007 |
Crandall CJ, Zheng Y, Karlamangla A, Sternfeld B, Habel LA, Oestreicher N, Johnston J, Cauley JA, Greendale GA. The association between mammographic breast density and bone mineral density in the study of women's health across the nation. Annals of Epidemiology. 17: 575-83. PMID 17532645 DOI: 10.1016/J.Annepidem.2007.03.012 |
0.334 |
|
| 2007 |
Carlson J, Oestreicher N, Lubeck DP, Ramsey SD, Veenstra DL. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 25: 7664-7664. DOI: 10.1200/Jco.2007.25.18_Suppl.7664 |
0.538 |
|
| 2006 |
Friedman GD, Oestreicher N, Chan J, Quesenberry CP, Udaltsova N, Habel LA. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 2102-6. PMID 17119034 DOI: 10.1158/1055-9965.Epi-06-0401 |
0.394 |
|
| 2005 |
Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 104: 2054-62. PMID 16216002 DOI: 10.1002/Cncr.21464 |
0.557 |
|
| 2005 |
Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genetics in Medicine : Official Journal of the American College of Medical Genetics. 7: 380-9. PMID 16024969 DOI: 10.1097/01.Gim.0000170776.31248.75 |
0.453 |
|
| 2004 |
Oestreicher N, Veenstra D, Linden H, McCune J, Ramsey S. CE3 THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS: COMPARISON OF ATTRIBUTABLE COST AND MICROCOSTING APPROACHES Value in Health. 7: 226. DOI: 10.1016/S1098-3015(10)62085-2 |
0.573 |
|
| 2000 |
Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E. Breast density as a predictor of mammographic detection: Comparison of interval- and screen-detected cancers Journal of the National Cancer Institute. 92: 1081-1087. PMID 10880551 DOI: 10.1093/JNCI/92.13.1081 |
0.306 |
|
| Show low-probability matches. |